Combination of an angiotensin II receptor blocker, a calcium channel blocker and another active agent

Details for Australian Patent Application No. 2006311723 (hide)

Owner Novartis AG

Inventors Webb, Randy Lee

Agent Davies Collison Cave

Pub. Number AU-A-2006311723

PCT Pub. Number WO2007/056324

Priority 60/734,700 08.11.05 US

Filing date 6 November 2006

Wipo publication date 18 May 2007

International Classifications

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61K 31/41 (2006.01) - having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole

A61K 31/4422 (2006.01) - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

Event Publications

22 May 2008 PCT application entered the National Phase

  PCT publication WO2007/056324 Priority application(s): WO2007/056324

10 March 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006311725-Compositions and methods for inhibiting expression of NAV1.8 gene

2006311719-Permittivity measurements with oilbased mud imaging tool